An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer ; volume:42 ; number:1 ; day:9 ; month:8 ; year:2023 ; pages:1-18 ; date:12.2023
Journal of experimental & clinical cancer research ; 42, Heft 1 (9.8.2023), 1-18, 12.2023
- Urheber
-
Montero, Juan Carlos
Carmen, Sofía del
Abad, Mar
Sayagués, José M.
Barbáchano, Antonio
Fernández-Barral, Asunción
Muñoz, Alberto
Pandiella, Atanasio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-023-02784-0
- URN
-
urn:nbn:de:101:1-2024013114465272371401
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Montero, Juan Carlos
- Carmen, Sofía del
- Abad, Mar
- Sayagués, José M.
- Barbáchano, Antonio
- Fernández-Barral, Asunción
- Muñoz, Alberto
- Pandiella, Atanasio
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110